

MEDICARE ADVANTAGE PRIOR AUTHORIZATION REQUEST FORM

Ustekinumab - Medicare

Phone: 215-991-4300 Fax back to: 866-371-3239

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.				
Member Name:		Prescriber Name:		
Member Number:		Fax:	Phone:	
Date of Birth:		Office Contact:		
Line of Business:	□ Medicare Advantage	NPI:	State Lic ID:	
Address:		Address:		
City, State ZIP:		City, State ZIP:		
Primary Phone:		Specialty/facility name (if applicable):		
REQUEST FOR EXPEDITED REVIEW: By checking this box and signing below, I certify that applying the 72 hour standard review timeframe may seriously jeopardize he life or health of the enrollee or the enrollee's ability to regain maximum function.				
Drug Name:				
Strength:				
Directions / SIG:				
Please attach any pertinent medical history including labs and information for this member that may support approval. Please answer the following questions and sign.				
Q1. Will the patient be taking this drug concomitantly with another biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) or a targeted synthetic DMARD?				
☐ Yes		□ No		
Q2. Is ustekinumab being prescribed by or in consultation with an appropriate specialist such as a dermatologist, rheumatologist, or gastroenterologist?				
☐ Yes		□ No		
Q3. Is this a request for reauthorization? If YES, go to 4. If NO, go to 5.				
☐ Yes		□ No		
Q4. Is there confirmation of positive clinical response?				
☐ Yes		□ No		
Q5. Are chart notes attached documenting a diagnosis of moderate to severe plaque psoriasis and is a candidate for phototherapy or systemic therapy? If YES, go to 6. If NO, go to 7.				
☐ Yes		□ No		

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



MEDICARE ADVANTAGE PRIOR AUTHORIZATION REQUEST FORM

Ustekinumab - Medicare

Phone: 215-991-4300 Fax back to: 866-371-3239

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Member Name:	Prescriber Name:		
Q6. Is there documentation of an inadequate response, intolerance, or contraindication to 1 of the following: methotrexate, ultraviolet-B (UVB) therapy, or acitretin?			
☐ Yes	□ No		
Q7. Are chart notes attached documenting a diagnosis of active Crohn's disease (CD)? If YES, go to 8. If NO, go to 9.			
☐ Yes	□ No		
Q8. Is there documentation of an inadequate response, intolerance, or contraindication to at least 1 of the following therapies: corticosteroids, methotrexate, 6-mercaptopurine, azathioprine?			
☐ Yes	□ No		
Q9. Are chart notes attached documenting an FDA-approved diagnosis not otherwise excluded from part D?			
☐ Yes	□ No		
Q10. Requested Duration:			
☐ 12 Months	☐ Other:		
Q11. Additional Information:			
Prescriber Signature	Date		

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document

v2026